Impact of Blood Parameters and Normal Tissue Dose on Treatment Outcome in Esophageal Cancer Patients Undergoing Neoadjuvant Radiochemotherapy
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patient Characteristics
2.2. Treatment
2.3. FDG PET Protocol and Data Analysis
2.4. Clinical Endpoints and Statistical Analysis
3. Results
3.1. Prognostic Factors for Overall Survival
3.2. Prognostic Factors for Local Tumor Control
3.3. Prognostic Factors for Freedom from Distant Metastases
3.4. Correlation of Dose Parameters, Blood Values and PET Data
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Zhang, Y. Epidemiology of esophageal cancer. World J. Gastroenterol. 2013, 19, 5598–5606. [Google Scholar] [CrossRef] [PubMed]
- Stahl, M.; Walz, M.K.; Stuschke, M.; Lehmann, N.; Meyer, H.J.; Riera-Knorrenschild, J.; Langer, P.; Engenhart-Cabillic, R.; Bitzer, M.; Königsrainer, A.; et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J. Clin. Oncol. Off. J. Soc. Clin. Oncol. 2009, 27, 851–856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Hagen, P.; Hulshof, M.C.; van Lanschot, J.J.; Steyerberg, E.W.; van Berge Henegouwen, M.I.; Wijnhoven, B.P.; Richel, D.J.; Nieuwenhuijzen, G.A.; Hospers, G.A.; Bonenkamp, J.J.; et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 2012, 366, 2074–2084. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eyck, B.M.; van Lanschot, J.J.B.; Hulshof, M.; van der Wilk, B.J.; Shapiro, J.; van Hagen, P.; van Berge Henegouwen, M.I.; Wijnhoven, B.P.L.; van Laarhoven, H.W.M.; Nieuwenhuijzen, G.A.P.; et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2021, 39, 1995–2004. [Google Scholar] [CrossRef]
- Bütof, R.; Hofheinz, F.; Zöphel, K.; Schmollack, J.; Jentsch, C.; Zschaeck, S.; Kotzerke, J.; van den Hoff, J.; Baumann, M. Prognostic value of SUR in patients with trimodality treatment of locally advanced esophageal carcinoma. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2018, 60, 192–198. [Google Scholar] [CrossRef] [Green Version]
- Li, C.; Lin, J.W.; Yeh, H.L.; Chuang, C.Y.; Chen, C.C. Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism. Sci. Rep. 2021, 11, 11626. [Google Scholar] [CrossRef]
- Borggreve, A.S.; Heethuis, S.E.; Boekhoff, M.R.; Goense, L.; van Rossum, P.S.N.; Brosens, L.A.A.; van Lier, A.; van Hillegersberg, R.; Lagendijk, J.J.W.; Mook, S.; et al. Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer. Eur. Radiol. 2020, 30, 1896–1907. [Google Scholar] [CrossRef] [Green Version]
- Cox, J.D. Are the results of RTOG 0617 mysterious? Int. J. Radiat. Oncol. Biol. Phys. 2012, 82, 1042–1044. [Google Scholar] [CrossRef]
- Bradley, J.D.; Paulus, R.; Komaki, R.; Masters, G.; Blumenschein, G.; Schild, S.; Bogart, J.; Hu, C.; Forster, K.; Magliocco, A.; et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): A randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015, 16, 187–199. [Google Scholar] [CrossRef] [Green Version]
- Davuluri, R.; Jiang, W.; Fang, P.; Xu, C.; Komaki, R.; Gomez, D.R.; Welsh, J.; Cox, J.D.; Crane, C.H.; Hsu, C.C.; et al. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes after Chemoradiation Therapy. Int. J. Radiat. Oncol. Biol. Phys. 2017, 99, 128–135. [Google Scholar] [CrossRef]
- Xu, C.; Jin, J.Y.; Zhang, M.; Liu, A.; Wang, J.; Mohan, R.; Kong, F.S.; Lin, S.H. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2020, 146, 180–186. [Google Scholar] [CrossRef]
- Hofheinz, F.; Li, Y.; Steffen, I.G.; Lin, Q.; Lili, C.; Hua, W.; van den Hoff, J.; Zschaeck, S. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1485–1494. [Google Scholar] [CrossRef]
- Zschaeck, S.; Hofheinz, F.; Zöphel, K.; Bütof, R.; Jentsch, C.; Schmollack, J.; Löck, S.; Kotzerke, J.; Baretton, G.; Weitz, J.; et al. Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 1813–1822. [Google Scholar] [CrossRef]
- Kong, F.M.; Ritter, T.; Quint, D.J.; Senan, S.; Gaspar, L.E.; Komaki, R.U.; Hurkmans, C.W.; Timmerman, R.; Bezjak, A.; Bradley, J.D.; et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: Atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 1442–1457. [Google Scholar] [CrossRef] [Green Version]
- Lin, J.B.; Hung, L.C.; Cheng, C.Y.; Chien, Y.A.; Lee, C.H.; Huang, C.C.; Chou, T.W.; Ko, M.H.; Lai, Y.C.; Liu, M.T.; et al. Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy. Radiat. Oncol. 2019, 14, 85. [Google Scholar] [CrossRef] [Green Version]
- Newman, N.B.; Anderson, J.L.; Sherry, A.D.; Osmundson, E.C. Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer. J. Thorac. Dis. 2020, 12, 2395–2405. [Google Scholar] [CrossRef]
- Cai, G.; Li, C.; Yu, J.; Meng, X. Heart Dosimetric Parameters Were Associated with Cardiac Events and Overall Survival for Patients with Locally Advanced Esophageal Cancer Receiving Definitive Radiotherapy. Front. Oncol. 2020, 10, 153. [Google Scholar] [CrossRef]
- Wang, X.; Palaskas, N.L.; Yusuf, S.W.; Abe, J.I.; Lopez-Mattei, J.; Banchs, J.; Gladish, G.W.; Lee, P.; Liao, Z.; Deswal, A.; et al. Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2020, 15, 1682–1690. [Google Scholar] [CrossRef]
- Wang, X.; Palaskas, N.L.; Hobbs, B.P.; Abe, J.I.; Nead, K.T.; Yusuf, S.W.; Hermann, J.; Deswal, A.; Lin, S.H. The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers 2022, 14, 1304. [Google Scholar] [CrossRef]
- Tseng, Y.D.; Maes, S.M.; Kicska, G.; Sponsellor, P.; Traneus, E.; Wong, T.; Stewart, R.D.; Saini, J. Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness. Radiat. Oncol. 2019, 14, 243. [Google Scholar] [CrossRef] [Green Version]
- Sun, T.; Lin, X.; Tong, Y.; Liu, X.; Pan, L.; Tao, C.; Duan, J.; Yin, Y. Heart and Cardiac Substructure Dose Sparing in Synchronous Bilateral Breast Radiotherapy: A Dosimetric Study of Proton and Photon Radiation Therapy. Front. Oncol. 2019, 9, 1456. [Google Scholar] [CrossRef]
- Xu, C.; Guo, L.; Liao, Z.; Wang, Y.; Liu, X.; Zhao, S.; Wang, J.; Yuan, Z.; Wang, P.; Lin, S.H. Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin. Transl. Radiat. Oncol. 2019, 17, 17–23. [Google Scholar] [CrossRef] [Green Version]
- Beukema, J.C.; Kawaguchi, Y.; Sijtsema, N.M.; Zhai, T.T.; Langendijk, J.A.; van Dijk, L.V.; van Luijk, P.; Teshima, T.; Muijs, C.T. Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients? Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2020, 149, 222–227. [Google Scholar] [CrossRef]
- Abravan, A.; Faivre-Finn, C.; Kennedy, J.; McWilliam, A.; van Herk, M. Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients with Lung Cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer 2020, 15, 1624–1635. [Google Scholar] [CrossRef]
- Chen, Y.; Zhang, Z.; Jiang, G.; Zhao, K. Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy. J. Thorac. Dis. 2016, 8, 1155–1161. [Google Scholar] [CrossRef] [Green Version]
- Boggs, D.H.; Hanna, A.; Burrows, W.; Horiba, N.; Suntharalingam, M. Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy. J. Gastrointest. Cancer 2015, 46, 131–137. [Google Scholar] [CrossRef]
- Jing, W.; Zhu, H.; Guo, H.; Zhang, Y.; Shi, F.; Han, A.; Li, M.; Kong, L.; Yu, J. Feasibility of Elective Nodal Irradiation (ENI) and Involved Field Irradiation (IFI) in Radiotherapy for the Elderly Patients (Aged ≥ 70 Years) with Esophageal Squamous Cell Cancer: A Retrospective Analysis from a Single Institute. PLoS ONE 2015, 10, e0143007. [Google Scholar] [CrossRef]
- Cheng, Y.J.; Jing, S.W.; Zhu, L.L.; Wang, J.; Wang, L.; Liu, Q.; Yang, C.R.; Wang, Y.; Cao, F.; Jiao, W.P.; et al. Comparison of elective nodal irradiation and involved-field irradiation in esophageal squamous cell carcinoma: A meta-analysis. J. Radiat. Res. 2018, 59, 604–615. [Google Scholar] [CrossRef] [Green Version]
- Li, M.; Zhang, X.; Zhao, F.; Luo, Y.; Kong, L.; Yu, J. Involved-field radiotherapy for esophageal squamous cell carcinoma: Theory and practice. Radiat. Oncol. 2016, 11, 18. [Google Scholar] [CrossRef] [Green Version]
- Bütof, R.; Hofheinz, F.; Zophel, K.; Stadelmann, T.; Schmollack, J.; Jentsch, C.; Lock, S.; Kotzerke, J.; Baumann, M.; van den Hoff, J. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2015, 56, 1150–1156. [Google Scholar] [CrossRef] [Green Version]
- Mamede, M.; Abreu, E.L.P.; Oliva, M.R.; Nose, V.; Mamon, H.; Gerbaudo, V.H. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: Correlation with histopathology results. Am. J. Clin. Oncol. 2007, 30, 377–388. [Google Scholar] [CrossRef] [PubMed]
- Lomas, H.; Hoffe, S.; Weber, J. Post Chemoradiation PET SUV is highly predictive of overall survival in esophageal cancer. J Nucl. Med. Radiat. Ther. 2012, 3, 125. [Google Scholar] [CrossRef]
- Zakem, S.J.; Jones, B.; Castillo, R.; Castillo, E.; Miften, M.; Goodman, K.A.; Schefter, T.; Olsen, J.; Vinogradskiy, Y. Cardiac metabolic changes on (18) F-positron emission tomography after thoracic radiotherapy predict for overall survival in esophageal cancer patients. J. Appl. Clin. Med. Phys. 2022, e13552. [Google Scholar] [CrossRef] [PubMed]
- Takanami, K.; Arai, A.; Umezawa, R.; Takeuchi, T.; Kadoya, N.; Taki, Y.; Jingu, K.; Takase, K. Association between radiation dose to the heart and myocardial fatty acid metabolic impairment due to chemoradiation-therapy: Prospective study using I-123 BMIPP SPECT/CT. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2016, 119, 77–83. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Median (Range) | Number of Patients | % |
---|---|---|---|
Age (years) | 61.3 (40.5–79.3) | - | - |
Body mass index (kg/m2) | 26.3 (16.7–43.6) | - | - |
Gender | Male | 113 | 90.4 |
Female | 12 | 9.6 | |
WHO status | 0 | 67 | 53.6 |
1 | 51 | 40.8 | |
2 | 2 | 1.6 | |
Unknown | 5 | 4.0 | |
Histology | Adenocarcinoma | 43 | 34.4 |
Squamous Cell Carcinoma | 82 | 65.6 | |
Clinical T-stage | 2 | 19 | 15.2 |
3 | 96 | 76.8 | |
4 | 7 | 5.6 | |
Unknown | 3 | 2.4 | |
Clinical N-stage | 0 | 14 | 11.2 |
1 | 89 | 71.2 | |
2 | 13 | 10.4 | |
3 | 2 | 1.6 | |
Unknown | 7 | 5.6 | |
Chemotherapy | Complete | 114 | 91.2 |
Prematurely Terminated | 11 | 8.8 |
Parameter | Median (Range) | Median (Range) |
---|---|---|
Staging | Restaging | |
Hb (mmol/L) | 8.20 (4.90–10.40) | 7.50 (5.20–9.50) |
Leucocytes (GPt/L) | 8.38 (4.07–26.02) | 3.36 (1.49–8.91) |
Thrombocytes (GPt/L) | 248 (98–573) | 152.5 (71–360) |
Lymphocytes (GPt/L) * | 1.63 (0.17–3.26) | 0.30 (0.12–3.11) |
Neutrophil Granulocytes (GPt/L) * | 5.26 (2.67–14.83) | 2.14 (0.61–6.78) |
Monocytes (GPt/L) * | 0.73 (0.02–1.72) | 0.48 (0.09–1.08) |
SUVmean_lung | 0.48 (0.30–0.95) | 0.49 (0.29–0.98) |
SUVmax_lung | 3.07 (1.66–11.02) | 2.56 (1.39–8.72) |
SUVmean_heart | 1.58 (1.05–6.35) | 1.59 (0.95–7.39) |
SUVmax_heart | 4.12 (1.93–24.81) | 3.83 (2.03–28.19) |
Dmean_lung (Gy) | 10.49 (1.55–20.20) | |
V20Gy_lung (%) | 15.95 (0.00–34.74) | |
Dmean_heart (Gy) | 26.10 (0.38–42.69) |
Parameter (Unit) | Hazard Ratio (95% Confidence Interval) | p-Value |
---|---|---|
Age (years) | 1.03 (1.00–1.06) | 0.083 |
Histology (squamous cell carcinoma vs. adenocarcinoma) | 0.63 (0.38–1.05) | 0.077 |
N-stage (N0 vs. > N0) | 3.80 (1.19–12.18) | 0.025 |
∆Hb (mmol/l) | 1.14 (0.79–1.65) | 0.48 |
∆Leukocytes (GPt/L) | 1.05 (0.96–1.14) | 0.28 |
∆Thrombocytes (GPt/L) | 1.00 (0.99–1.00) | 0.19 |
Restaging lymphocytes (GPt/L) | 12.29 (1.65–91.55) | 0.014 |
Surgical complication (yes/no) | 1.93 (1.01–3.69) | 0.047 |
Dmean_lung (Gy) | 1.17 (1.09–1.26) | <0.001 |
V20Gy_lung (%) | 1.08 (1.04–1.12) | <0.001 |
Dmean_heart (Gy) | 1.07 (1.03–1.11) | 0.002 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bütof, R.; Häberlein, L.; Jentsch, C.; Kotzerke, J.; Lohaus, F.; Makocki, S.; Valentini, C.; Weitz, J.; Löck, S.; Troost, E.G.C. Impact of Blood Parameters and Normal Tissue Dose on Treatment Outcome in Esophageal Cancer Patients Undergoing Neoadjuvant Radiochemotherapy. Cancers 2022, 14, 3504. https://doi.org/10.3390/cancers14143504
Bütof R, Häberlein L, Jentsch C, Kotzerke J, Lohaus F, Makocki S, Valentini C, Weitz J, Löck S, Troost EGC. Impact of Blood Parameters and Normal Tissue Dose on Treatment Outcome in Esophageal Cancer Patients Undergoing Neoadjuvant Radiochemotherapy. Cancers. 2022; 14(14):3504. https://doi.org/10.3390/cancers14143504
Chicago/Turabian StyleBütof, Rebecca, Laura Häberlein, Christina Jentsch, Jörg Kotzerke, Fabian Lohaus, Sebastian Makocki, Chiara Valentini, Jürgen Weitz, Steffen Löck, and Esther G. C. Troost. 2022. "Impact of Blood Parameters and Normal Tissue Dose on Treatment Outcome in Esophageal Cancer Patients Undergoing Neoadjuvant Radiochemotherapy" Cancers 14, no. 14: 3504. https://doi.org/10.3390/cancers14143504